Intravenous Ketorolac for Postoperative Pain in Laparoscopic Donor Nephrectomy

Mayo Clinic

Status and phase: Completed; Phase 4

Conditions: Laparoscopic Donor Nephrectomy; Nephrectomy

Treatments: Drug: Ketorolac; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT00765232

08-000747 LDN

Details and patient eligibility

About

The purpose of this study is to determine whether continuous intravenous ketorolac infusion reduces pain in patients who are having laparoscopic surgery to donate a kidney.

Enrollment: 111 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients donating a kidney via laparoscopic donor nephrectomy

Exclusion criteria

• History of NSAID allergy
• Asthma
• History of long term opioid use
• Intraoperative blood loss greater than 300 mL
• Postoperative hemodynamic instability
• Active peptic ulcer disease
• Advanced renal impairment (Cr > 2.0 mg/dL)
• Bleeding diathesis
• Current use of probenecid
• Pregnancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

111 participants in 2 patient groups, including a placebo group

Ketorolac

Experimental group

Description:

90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.

Treatment:

Drug: Ketorolac

Placebo

Placebo Comparator group

Description:

1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.

Treatment:

Drug: Placebo